5-Year Outcomes Following A HIFU Focal Therapy Study Demonstrate Impressive Disease Control And Low Side Effect Profile For Prostate Cancer Patients In The U.K.

Sonablate® HIFU used in study to treat clinically significant nonmetastatic prostate cancer achieves complete pad-free urinary continence in 98% of men. CHARLOTTE, N.C., July 5, 2018 -- (Healthcare Sales & Marketing Network) -- SonaCare Medical, th... Devices, Oncology SonaCare Medical, HIFU , Sonablate, prostate cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news